3-4-99

FEB 1 9 1999

SERVICE CENTE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DECENTED

In re application of:

De FLORA et al.

Serial Number: 09/125,022

Filed: November 24, 1998

Group Art Unit: 1623

Examiner: Unknown

For: PHARMACEUTICAL COMPOSITION ENABLING TO INHIBIT CANCER

METASTASIS FORMATION CONTAINING N-ACETYL-CYSTEINE AND

DOXORUBICIN

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D. C. 20231

February 18, 1999

Sir:

In compliance with applicant's duty of disclosure under 37 C.F.R. §1.56, the following is material information of which applicants are aware, and which is relevant to the above-identified application:

The references, which are listed on the attached PTO form 1449 are mentioned in the specification, and therefore, need no further explanation.

A copy of the above-cited references and the International Search Report issued in the corresponding International application are attached hereto.

Applicant's submit these documents not more than three months after the filling date and before a first official action on the merits, therefore, no fee is required.

Should any additional fees be due with respect to this paper, such fees may be charged to Counsel's Deposit Account No. 14-1060.

Respectfully submitted,

NIKAIDO, MARMELSTEIN, MURRAY & ORAM LLP

Jámes A. Poulos, III Attorney for Applicants Registration No. 31,714

Atty. Docket No. P8903-8035

Metropolitan Square 655 Fifteenth Street, N.W. Suite 330 - G Street Lobby Washington, D.C. 20005-5701 (202) 638-5000

POU:fcs

Enclosures: PTO-1449

Documents (12)

International Search Report

BEST AVAILABLE COPY